MARKET

SNSS

SNSS

Sunesis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4200
-0.0225
-5.08%
After Hours: 0.4298 +0.0098 +2.33% 17:58 03/27 EDT
OPEN
0.4361
PREV CLOSE
0.4425
HIGH
0.4365
LOW
0.3995
VOLUME
912.73K
TURNOVER
--
52 WEEK HIGH
1.770
52 WEEK LOW
0.1951
MARKET CAP
46.79M
P/E (TTM)
-1.4508
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SNSS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNSS stock price target is 2.667 with a high estimate of 6.00 and a low estimate of 1.000.

EPS

SNSS News

More
  • Edited Transcript of SNSS earnings conference call or presentation 10-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?
  • Zacks · 03/17 16:30
  • Earnings Beat: Sunesis Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
  • Simply Wall St. · 03/13 17:56
  • Benzinga's Top Upgrades, Downgrades For March 11, 2020
  • Benzinga · 03/11 13:33

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SNSS

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
More

Webull offers kinds of Sunesis Pharmaceuticals, Inc. stock information, including NASDAQ:SNSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNSS stock news, and many more online research tools to help you make informed decisions.